Enterogermina suspension 5 ml #20 (10×2)

Enterogermina® is a suspension of spores of 4 strains (SIN, O/C, T, N/R) of Bacillus clausii, which are normally present in the intestine and do not show pathogenic activity.

Spores are inherently capable of tolerating high temperature and gastric acidity. In a validated in vitro model, Bacillus clausii spores demonstrated the ability to survive in a model simulating gastric environment (pH 1.4-1.5) for up to 120 minutes (survival rate of 96%). In a model simulating an intestinal environment (bile and pancreatin saline solution – pH 8), Bacillus clausii spores demonstrated the ability to proliferate over initial numbers in a statistically significant manner (109 to 1012 colony-forming units (CFU)) starting 240 minutes after incubation. In a study involving 20 participants, it was noted that in humans, Bacillus clausii spores reside permanently in the intestine and can be detected in feces for up to 12 days after a single oral ingestion.

Thanks to the action of Bacillus clausii, the drug restores intestinal microflora altered as a result of drug therapy leading to dysbacteriosis (also known as dysbiosis), which may also be associated with gastrointestinal symptoms such as diarrhea, abdominal pain and flatulence (intestinal bloating). In addition, due to the ability of Bacillus clausii to synthesize different vitamins, especially B vitamins, the drug helps to correct dysvitaminosis caused by the use of antibiotics or chemotherapeutic drugs. Due to the metabolic activity of Bacillus clausii, the use of the drug allows to achieve nonspecific antigenic and antitoxic effects.

Due to its high resistance to chemical and physical agents, Bacillus clausii spores pass unharmed through the gastric juice barrier into the intestine, where they transform into metabolically active vegetative cells.

In two open-label randomized controlled clinical trials, the drug Enterogermina® demonstrated a reduction in the duration of acute diarrhea in children 6 months of age and older.

When taken during antibiotic treatment and for the next 7-10 days, Enterojermina® has demonstrated a reduction in the incidence of abdominal pain and diarrhea associated with antibiotic treatment.